Actions of selected cardiovascular hormones on arterial stiffness and wave reflections

Current Pharmaceutical Design

Volumn 15, Issue 3, 2009, Pages 304-320

  Nichols, Wilmer W ^a   Epstein, Benjamin J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Arterial stiffness; Augmentation index; Cardiovascular hormones; Central blood pressure; Endothelium; Tension time index; Wasted left ventricular energy; Wave reflection

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; EPROSARTAN; ESTRADIOL; ESTROGEN; GESTAGEN; INDAPAMIDE; IRBESARTAN; LOSARTAN; NITRATE; NITRIC OXIDE; PERINDOPRIL; PLACEBO; PROGESTERONE; RAMIPRIL; TESTOSTERONE; UNINDEXED DRUG; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTERY WALL; AUGMENTATION INDEX; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; ENERGY CONSUMPTION; ENERGY EXPENDITURE; ESSENTIAL HYPERTENSION; ESTROGEN THERAPY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MUSCLE RELAXATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARTERIES; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCLE, SMOOTH, VASCULAR; VASODILATOR AGENTS;

EID: 62249156175     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787354258     Document Type: Review

References (232)

1. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358: 1504-7.
2. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008; 358: 2545-59
3. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: The Strong Heart Study. Hypertension 2007; 50: 197-203.
4. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Perez G, et al. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 2005; 96: 645-8.
5. Sever PS, Poulter NR, Elliott WJ, Jonsson MC, Black HR, Sever PS, et al. Blood pressure reduction is not the only determinant of outcome Circulation 2006; 113: 2754-72.
6. Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18: 599-606.
7. Mallareddy M, Parikh CR, Peixoto AJ. Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: Systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2006; 8: 398-403.
8. Mahmud A, Feely J. Arterial Stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone System 2004; 5: 102-8.
9. Nichols WW, Denardo SJ, Wilkinson IB, McEniery CM, Cockcroft J, O'Rourke MF. Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform. J Clin Hypertens (Greenwich) 2008; 10: 295-303.
10. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 2007; 49: 1202-6.
11. Laurent S, Boutouyrie P. Arterial stiffness: A new surrogate end point for cardiovascular disease? J Nephrol 2007; 20(Suppl 12): S45-50.
12. O'Rourke MF. Basic concepts for the understanding of large arteries in hypertension. J Cardiovasc Pharmacol 1985; 7(Suppl 2): S14-21.
13. Nichols WW, O'Rourke MF. McDonald's Blood Flow in Arteries: Theoretic, Experimental and Clinical Principles. 5th ed. Edward Arnold: London; 2005.
14. Hamilton PK, Lockhart CJ, Quinn CE, McVeigh GE. Arterial stiffness: clinical relevance, measurement and treatment. Clin Sci (Lond) 2007; 113: 157-70.
15. Inoue T, Matsuoka M, Nagahama K, Iseki C, Touma T, Iseki K, et al. Cardiovascular risk factors associated with pulse pressure in a screened cohort in Okinawa, Japan. Hypertens Res 2003; 26: 153-8.
16. Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34: 1203-6.
17. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients Hypertension 2001; 37: 1236-41.
18. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-5.
19. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-15.
20. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. Normal vascular aging: Differential effects on wave reflection and aortic pulse wave velocity: The Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005; 46: 1753-60.
21. Najjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2008; 51: 1377-83.
22. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: Comparison with atenolol. J Am Coll Cardiol 2004; 43: 92-9.
23. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.
24. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, et al. Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: The prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007; 49: 1271-7.
25. Dart AM, Cameron JD, Gatzka CD, Willson K, Liang YL, Berry KL, et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension 2007; 49: 1242-7.
26. O'Rrourke MF, Hashimoto J. Arterial stiffness: A modifiable cardiovascular risk factor? J Cardiopulm Rehabil Prev 2008; 28: 225-237.
27. Wilkinson IB, MacCallum H, Hupperetz PC, van Thoor CJ, Cockcroft JR, Webb DJ. Changes in the derived central pressure wave-form and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol 2001; 530: 541-50.
28. Smith JC, Page MD, John R, Wheeler MH, Cockcroft JR, Scanlon MF, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3515-9.
29. Owen PJ, Rajiv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab 2006; 91: 2126-32.
30. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 1999; 33: 1118-22.
31. Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab 2006; 290: E234-42.
32. Wang YX, Fitch RM. Vascular stiffness: Measurements, mechanisms and implications. Curr Vasc Pharmacol 2004; 2: 379-84.
33. Hillebrand U, Hausberg M, Lang D, Stock C, Riethmüller C, Callies C, et al. How steroid hormones act on the endothelium-insights by atomic force microscopy. Pflugers Arch 2008; 456: 51-60.
34. Safar ME, Lacolley P. Disturbance of macro- and microcirculation: relations with pulse pressure and cardiac organ damage. Am J Physiol Heart Circ Physiol 2007; 293: H1-7.
35. McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007; 34: 665-71.
36. Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Aortic input impedance in normal man: Relationship to pressure wave forms. Circulation 1980; 62: 105-16.
37. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18: 3S-10S.
38. Boutouyrie P, Laurent S, Benetos A, Girerd XJ, Hoeks AP, Safar ME. Opposing effects of ageing on distal and proximal large arteries in hypertensives. J Hypertens Suppl 1992; 10: S87-91.
39. Bortolotto LA, Hanon O, Franconi G, Boutouyrie P, Legrain S, Girerd X. The aging process modifies the distensibility of elastic but not muscular arteries. Hypertension 1999; 34: 889-92.
40. Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res 1987; 21: 678-87.
41. Ahlgren AR, Astrand H, Sandgren T, Vernersson E, Sonesson B, Lanne T. Dynamic behaviour of the common femoral artery: Age and gender of minor importance. Ultrasound Med Biol 2001; 27: 181-8.
42. Ahlgren AR, Hansen F, Sonesson B, Lanne T. Stiffness and diameter of the common carotid artery and abdominal aorta in women. Ultrasound Med Biol 1997; 23: 983-8.
43. van der Heijden-Spek JJ, Staessen JA, Fagard RH, Hoeks AP, Boudier HA, van Bortel LM. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: A population study. Hypertension 2000; 35: 637-42.
44. Cameron JD, Bulpitt CJ, Pinto ES, Rajkumar C. The aging of elastic and muscular arteries: A comparison of diabetic and nondiabetic subjects. Diabetes Care 2003; 26: 2133-8.
45. Kimoto E, Shoji T, Shinohara K, Inaba M, Okuno Y, Miki T, et al. Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 2003; 52: 448-52.
46. Nichols WW, Edwards DG. Arterial elastance and wave reflection augmentation of systolic blood pressure: Deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther 2001; 6: 5-21
47. Nichols WW. Determinants of systolic hypertension in older persons. In: Hosoda S, Yaginuma T, Sugawara, M, Taylor MG, Caro CG, Eds. Recent Progress in Cardiovascular Mechanics. Australia, Harwood Academic Publishers 1994; 315-32.
48. Van Den Bos GC, Westerhof N, Elzinga G, Sipkema P. Reflection in the systemic arterial system: Effects of aortic and carotid occlusion. Cardiovasc Res 1976; 10: 565-73.
49. Sarnoff SJ, Braunwald E, Welch GH jr, Case RB, Stainsby WN, Macruz R. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol 1958; 192: 148-56.
50. Buckberg GD, Archie JP, Fixler DE, Hoffman JI. Experimental subendocardial ischemia during left ventricular hypertension. Surg Forum 1971; 22: 124-5.
51. Buckberg GD, Towers B, Paglia DE, Mulder DG, Maloney JV. Subendocardial ischemia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1972; 64: 669-84.
52. Buckberg GD, Fixler DE, Archie JP, Hoffman JI. Experimental subendocardial ischemia in dogs with normal coronary arteries. Circ Res 1972; 30: 67-81.
53. Ferro G, Spinelli L, Duilio C, Spadafora M, Guarnaccia F, Condorelli M. Diastolic perfusion time at ischemic threshold in patients with stress-induced ischemia. Circulation 1991; 84: 49-56.
54. Ferro G, Duilio C, Spinelli L, Liucci GA, Mazza F, Indolfi C. Relation between diastolic perfusion time and coronary artery stenosis during stress-induced myocardial ischemia. Circulation 1995; 92: 342-7.
55. Braunwald E, Sarnoff SJ, Case RB, Stainsby WN, Welch GH jr. Hemodynamic determinants of coronary flow: Effect of changes in aortic pressure and cardiac output on the relationship between myocardial oxygen consumption and coronary flow. Am J Physiol 1958; 192: 157-63.
56. Kingwell BA, Waddell TK, Medley TL, Cameron JD, Dart AM. Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 773-9.
57. Fischer GM, Swain ML. Effect of sex hormones on blood pressure and vascular connective tissue in castrated and non-castrated male rats. Am J Physiol 1977; 232: H617-21.
58. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-9.
59. Crews JK, Khalil RA. Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol. 1999; 19: 1034-40.
60. McGrath BP, Liang YL, Teede H, Shiel LM, Cameron JD, Dart A. Age-related deterioration in arterial structure and function in postmenopausal women: Impact of hormone replacement therapy. Arterioscler Thromb Vasc Biol 1998; 18: 1149-56.
61. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993; 88: 2163-71.
62. Baron YM, Galea R, Brincat M. Carotid artery wall changes in estrogen-treated and -untreated postmenopausal women. Obstet Gynecol 1998; 91: 982-6.
63. Westendorp IC, in 't Veld BA, Bots ML, Akkerhuis JM, Hofman A, Grobbee DE, et al. Hormone replacement therapy and intimamedia thickness of the common carotid artery: The Rotterdam study. Stroke 1999; 30: 2562-7.
64. Liang YL, Teede H, Shiel LM, Thomas A, Craven R, Sachithanandan N, et al. Effects of oestrogen and progesterone on age-related changes in arteries of postmenopausal women. Clin Exp Pharmacol Physiol 1997; 24: 457-9.
65. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Rajzer M, Jankowski P. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002; 16: 509-16.
66. Mihmanli V, Mihmanli I, Atakir K, Kantarci F, Aydin T, Sengun Y, et al. Carotid intima-media thickness in surgical menopause: Women who received HRT versus who did not. Maturitas 2002; 42: 37-43.
67. Takahashi K, Tanaka E, Murakami M, Mori-Abe A, Kawagoe J, Takata K, et al. Long-term hormone replacement therapy delays the age related progression of carotid intima-media thickness in healthy postmenopausal women. Maturitas 2004; 49: 170-7.
68. Nabulsi AA, Folsom AR, Szklo M, White A, Higgins M, Heiss G. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996; 4: 1857-63.
69. Sulistiyani, Adelman SJ, Chandrasekaran A, Jayo J, St Clair RW. Effect of 17 alpha-dihydroequilin sulfate, a conjugated equine estrogen, and ethynylestradiol on atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 837-46.
70. Williams JK, Anthony MS, Honore EK, Herrington DM, Morgan TM, Register TC, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995; 15: 827-36.
71. Henneman DH. Effect of estrogen on in vivo and in vitro collagen biosynthesis and maturation in old and young female guinea pigs. Endocrinology 1968; 83,678-90.
72. Fischer GM, Bashey RI, Rosenbaum H, Lyttle CR. A possible mechanism in arterial wall for mediation of sex difference in atherosclerosis. Exp Mol Pathol 1985; 43: 288-96.
73. Fischer GM, Swain ML. Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1985; 54: 177-85.
74. Fischer GM, Cherian K, Swain ML. Increased synthesis of aortic collagen and elastin in experimental atherosclerosis. Inhibition by contraceptive steroids. Atherosclerosis 1981; 39: 463-7.
75. Fischer GM, Swain ML. Effect of sex hormones on blood pressure and vascular connective tissue in castrated and non-castrated male rats. Am J Physiol 1977; 232: H617-21.
76. Nagai Y, Earley CJ, Kemper MK, Bacal CS, Metter EJ. Influence of age and postmenopausal estrogen replacement therapy on carotid arterial stiffness in women. Cardiovasc Res 1999; 41: 307-11.
77. Bui MN, Arai AE, Hathaway L, Waclawiw MA, Csako G, Cannon RO 3rd. Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women. Am J Cardiol 2002; 90: 82-5.
78. Moreau KL, Donato AJ, Seals DR, DeSouz a CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res 2003; 57: 861-8.
79. Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: A randomized, controlled trial. J Am Coll Cardiol 2000; 36: 1789-96.
80. Rodriguez-Macias KA, Naessen T, Bostrom A, Bergqvist D. Arterial stiffness is not improved in long-term use of estrogen. Am J Obstet Gynecol 2002; 186: 189-94.
81. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
82. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.
83. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 2002; 15: 426-44.
84. Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment of arterial stiffness in clinical practice. QJM 2002; 95: 67-74.
85. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23: 554-66.
86. Sztejnsznajd C, Silva ME, Nussbacher A, Gebara OE, D'Amico EA, Rocha DM, et al. Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus. Metabolism 2006; 55: 953-9.
87. Waddell TK, Rajkumar C, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. J Hypertens 1999; 17: 413-8.
88. Teede HJ, Liang YL, Kotsopoulos D, Zoungas S, Cravent R, McGrath BP. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: Effects on arterial compliance and endothelial function. Clin Endocrinol (Oxf) 2001; 55: 673-82.
89. Scuteri A, Lakatta EG, Bos AJ, Fleg JL. Effect of estrogen and progestin replacement on arterial stiffness indices in postmenopausal women. Aging (Milano) 2001; 13: 122-30.
90. Miura S, Tanaka E, Mori A, Toya M, Takahashi K, Nakahara K, et al. Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 2003; 45: 293-8.
91. da Costa LS, de Oliveira MA, Rubim VS, Wajngarten M, Aldrighi JM, Rosano GM, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004; 94: 1453-6.
92. Tsioufis C, Tzioumis K, Dimitriadis K, Chatzis D, Skiadas I, Michailidis A, et al. Nondipping status does not attenuate the conjugated estrogen-induced impovement in aortic stiffness in postmenopausal women with untreated hypertension. Am J Hypertens 2005; 18: 607-11.
93. Sumino H, Ichikawa S, Kasama S, Takahashi T, Kumakura H, Takayama Y, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; 189: 436-42.
94. London GM. Brachial arterial pressure to assess cardiovascular structural damage: An overview and lessons from clinical trials. J Nephrol 2008; 21: 23-31.
95. O'Rourke MF, Seward JB. Central arterial pressure and arterial pressure pulse: New views entering the second century after Korotkov. Mayo Clin Proc 2006; 81: 1057-68.
96. Sewdarsen M, Jialal I, Vythilingum S, Desai R. Sex hormone levels in young Indian patients with myocardial infarction. Arteriosclerosis 1986; 6: 418-21.
97. Phillips GB, Pinkernell BH, Jing TY. The association of hypotesto-steronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701-6.
98. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-4.
99. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004; 109: 184-9.
100. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008; 101: 618-24.
101. Oparil S, Haber E. The renin-angiotensin system (first of two parts). N Engl J Med 1974; 291: 389-401.
102. Oparil S, Haber E. The renin-angiotensin system (second of two parts). N Engl J Med 1974; 291: 446-57.
103. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-52
104. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
105. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993; 91: 2268-74.
106. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79: 748-56.
107. Benetos A, Levy BI, Lacolley P, Taillard F, Duriez M, Safar ME. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17: 3196-201.
108. Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Saito Y, Kurabayashi M. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28: 937-43.
109. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A
110. Raizada MK, Ferreira AJ. ACE2: A new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007; 5: 112-9.
111. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50: 1897-903.
112. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-13.
113. Saris JJ, 't Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-71.
114. Rehman A, Rahman AR, Rasool AH. Effect of angiotensin II on PWV in humans is mediated through angiotensin II type 1 (AT) receptors. J Hum Hypertens 2002; 16: 261-6.
115. Rehman A, Rasool AH, Naing L, Roshan TM, Rahman AR. Influence of the Angiotensin II type I receptor gene 1166A > C polymorphism on BP and aortic PWV among Malays. Ann Hum Genet 2007; 71: 86-95.
116. Gardier S, Vincent M, Lantelme P, Rial MO, Bricca G, Milon H. A1166C polymorphism of angiotensin II type 1 receptor, blood pressure and arterial stiffness in hypertension. J Hypertens 2004; 22: 2135-42.
117. Díez J, Laviades C, Orbe J, Zalba G, López B, González A, et al. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens 2003; 21: 2085-92
118. Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, et al. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001; 19: 407-13.
119. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081-4.
120. Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996; 94: 698-703.
121. Benetos A, Topouchian J, Ricard S, Gautier S, Bonnardeaux A, Asmar R, et al. Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients. Hypertension. 1995; 26: 44-7.
122. Safar ME, Benetos A. Factors influencing arterial stiffness in systolic hypertension in the elderly: Role of sodium and the reninangiotensin system. Am J Hypertens 2003; 16: 249-58.
123. Rehman A, Rahman AR, Rasool AH, Naing NN. The effects of angiotensin II on PWV in healthy humans. Int J Clin Pharmacol Ther 2001; 39: 423-30.
124. Lage SG, Kopel L, Medeiros CC, Carvalho RT, Creager MA. Angiotensin II contributes to arterial compliance in congestive heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H1424-9.
125. Everett AD, Tufro-McReddie A, Fisher A, Gomez A. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension 1994; 23: 587-592.
126. Schmieder RE, Messerli FH, Garavaglia GE, Nunez B, MacPhee AA, Re RN. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med 1988; 84(Suppl 3A): 136-139.
127. Clarkson PB, Wheeldon NM, MacLeod C, Tennent M, MacDonald TM. Effects of angiotensin II and aldosterone on diastolic function in vivo in normal man. Clin Sci (Lond) 1994; 87: 397-401.
128. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J 2007; 54: 359-70
129. Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 2007; 7: 151-7
130. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-7.
131. Brülla CG, Pick R, Tan LB, icki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-64.
132. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003; 42: 156-60.
133. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103: 425-31.
134. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, et al. Association between increased plasma levels of aldosterone and reased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10: 1326-34.
135. Lombès M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71: 503-10.
136. Park S, Kim JB, Shim CY, Ko YG, Choi D, g Y, Chung N. The influence of serum aldosterone and the aldosterone-renin ratio on PWV in hypertensive patients. J Hypertens 2007; 25: 1279-83.
137. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18: 50-5.
138. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004; 13: 513-9.
139. Folkow B. Physiological aspects of primary hypertension. Physio Rev 1982; 62: 347-504.
140. Mancia G. Bjorn Folkow Award Lecture: The sympathetic nervous system in hypertension. J Hypertens 1997; 15: 1553-1565.
141. Mancia G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl 2006; 24: S51-6.
142. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-8.
143. Heagerty AM. Structural changes in resistance arteries in hypertension. In: Zanchetti A, Mancia G, eds. Handbook of Hypertension, Vol 17: Pathophysiology of Hypertension. Amsterdam, Netherlands: Elsevier Science. 1997; 426-437.
144. Mangoni AA, Mircoli L, Giannattasio C, Mancia G, Ferrari AU. Effects of sympathectomy on mechanical properties of common carotid and femoral arteries. Hypertension 1997; 30: 1085-1088.
145. Lacolley P, Glaser E, Challande P, Boutouyrie P, Mignot JP, Duriez M, et al. Structural changes and in situ aortic pressure-diameter relationship in long-term chemical-sympathectomized rats. Am J Physiol 1995; 269: H407-16.
146. Mangoni AA, Mircoli L, Giannattasio C, Mancia G, Ferrari AU. Effect of sympathectomy on mechanical properties of common carotid and femoral arteries. Hypertension 1997; 30: 1085-8.
147. Failla M, Grappiolo A, Emanuelli G, Vitale G, Fraschini N, Giannattasio C, et al. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens 1999; 17: 1117-1124
148. Boutouyrie P, Lacolley P, Girerd X, Beck L, Safar M, Laurent S. Sympathetic activation reases medium-sized arterial compliance in humans. Am J Physiol 1994; 267: H1368-76.
149. Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. Beta-adrenergic receptor genes are associated with arterial stiffness in black and white adults: The Bogalusa Heart Study. Am J Hypertens 2007; 20: 1251-7.
150. Yuan M, Ohishi M, Ito N, Sugimoto K, Takagi T, Terai M, et al. Genetic influences of beta-adrenoceptor polymorphisms on arterial functional changes and cardiac remodeling in hypertensive patients. Hypertens Res 2006; 29: 875-81.
151. Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and PWV in humans. Hypertension 2003; 41: 1253-8.
152. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, et al. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant. 1998; 13: 375-83.
153. Karakitsos D, Patrianakos AP, Parthenakis FI, Malliaraki N, Nikitovic D, Kyriazis J, et al. Altered proximal aortic stiffness and endothelin plasma levels in diabetic patients with end-stage renal disease. ASAIO J 2007; 53: 343-50.
154. McEniery CM, Qasem A, Schmitt M, Avolio AP, Cockcroft JR, Wilkinson IB. Endothelin-1 regulates arterial PWV in vivo. J Am Coll Cardiol 2003; 42: 1975-81.
155. Khazaei M, Moien-Afshari F, Laher I. Vascular endothelial function in health and diseases. Pathophysiology 2008; 15: 49-67.
156. Smulyan H. Nitrates, arterial function, wave reflections and coronary heart disease. Adv Cardiol 2007; 44: 302-14.
157. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res. 1991; 68: 847-55.
158. Latson TW, Hunter WC, Katoh N, Sagawa K. Effect of nitroglycerin on aortic impedance, diameter, and pulse-wave velocity. Circ Res 1988; 62: 884-90.
159. Gnasso A, Carallo C, Irace C, De Franceschi MS, Mattioli PL, Motti C, et al. Association between wall shear stress and flow-mediated vasodilation in healthy men. Atherosclerosis 2001; 156: 171-6.
160. Pyke KE, Dwyer EM, Tschakovsky ME. Impact of controlling shear rate on flow-mediated dilation responses in the brachial artery of humans. J Appl Physiol 2004; 97: 499-508.
161. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol 2006; 23: 5: 4.
162. Reneman RS, Arts T, Hoeks AP. Wall shear stress - an important
163. Gilligan DM, Panza JA, Kilcoyne CM, Waclawiw MA, Casino PR, Quyyumi AA. Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. Circulation 1994; 90: 2853-8.
164. Bank AJ, Kaiser DR, Rajala S, Cheng A. In vivo human brachial artery elastic mechanics: Effects of smooth muscle relaxation. Circulation 1999; 100: 41-7.
165. Fitchett DH, Simkus GJ, Beaudry JP, Marpole DG. Reflected pressure waves in the ascending aorta: Effect of glyceryl trinitrate. Cardiovasc Res 1988; 22: 494-500.
166. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002; 53: 189-92.
167. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105: 213-7.
168. Weber T, Maas R, Auer J, Lamm G, Lassnig E, Rammer M, et al. Arterial wave reflections and determinants of endothelial function a hypothesis based on peripheral mode of action. Am J Hypertens 2007; 20: 256-62.
169. Jadhav UM, Kadam NN. Non-invasive assessment of arterial stiffness by pulse-wave velocity correlates with endothelial dysfunction. Indian Heart J 2005; 57: 226-32.
170. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006; 48: 602-8.
171. Stewart AD, Millasseau SC, Kearney MT, Ritter JK Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003; 42: 915-8.
172. Sugawara J, Komine H, Hayashi K, Yoshizawa M, Yokoi T, Otsuki T, et al. Effect of systemic nitric oxide synthase inhibition on arterial stiffness in humans. Hypertens Res 2007; 30: 411-5.
173. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 2002; 106: 2561-6.
174. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: From physiology to pharmacology. Hypertension 2004; 44: 112-6.
175. Westerbacka J, Uosukainen A, Mäkimattila S, Schlenzka A, Yki-Järvinen H. Insulin-induced decrease in large artery stiffness is impaired in uncomplicated type 1 diabetes mellitus. Hypertension 2000; 35: 1043-8.
176. Iemitsu M, Maeda S, Otsuki T, Sugawara J, Kuno S, Ajisaka R, et al. Arterial stiffness, physical activity, and atrial natriuretic Peptide gene polymorphism in older subjects. Hypertens Res 2008; 31: 767-74.
177. Schmitt M, Qasem A, McEniery C, Wilkinson IB, Tatarinoff V, Noble K, et al. Role of natriuretic peptides in regulation of conduit artery distensibility. Am J Physiol Heart Circ Physiol 2004; 287: H1167-71.
178. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50: 321-8.
179. Shub C, Klein AL, Zachariah PK, Bailey KR, Tajik AJ. Determination of left ventricular mass by echocardiography in a normal population: Effect of age and sex in addition to body size. Mayo Clin Proc 1994; 69: 205-11.
180. Gatzka CD, Kingwell BA, Cameron JD, Berry KL, Liang YL, Dewar EM, et al. Gender differences in the timing of arterial wave reflection beyond differences in body height. J Hypertens 2001; 19: 2197-203.
181. Hayward CS, Knight DC, Wren BG, Kelly RP. Effect of hormone replacement therapy on non-invasive cardiovascular haemodynamics. J Hypertens 1997; 15: 987-93.
182. Hayward CS, Samaras K, Campbell L, Kelly RP. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens 2001; 14: 699-703.
183. Hayward CS, Kalnins WV, Kelly RP. Acute effects of 17beta-estradiol on ventricular and vascular hemodynamics in postmenopausal women. Am J Physiol Heart Circ Physiol 2000; 279: H2277-84.
184. Stefanadis C, Tsiamis E, Dernellis J, Toutouzas P. Effect of estrogen on aortic function in postmenopausal women. Am J Physiol 1999; 276: H658-62.
185. Elsheikh M, Bird R, Casadei B, Conway GS, Wass JA. The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. J Clin Endocrinol Metab 2000; 85: 614-8.
186. Sztejnsznajd C, Silva ME, Nussbacher A, Gebara OE, D'Amico EA, Rocha DM, et al. Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus. Metabolism 2006; 55: 953-9.
187. Tanaka H, DeSouza CA, Seals DR. Arterial stiffness and hormone replacement use in healthy postmenopausal women. J Gerontol A Biol Sci Med Sci 1998; 53: M344-6.
188. Tentolouris N, Christodoulakos G, Lambrinoudaki I, Mandalaki E, Panoulis C, Maridaki C, et al. Effect of hormone therapy on the elastic properties of the arteries in healthy postmenopausal women. J Endocrinol Invest 2005; 28: 305-11.
189. Nichols WW, Pierce GL, Braith, RW, Does hormone treatment alter arterial properties in post menopausal women? Expert Rev Endocrinol Metab 2007; 2: 653-665.
190. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008; 51: 519-28.
191. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51: 1306-11.
192. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-76.
193. Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI, Safar ME, Benetos A. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 1994; 23: 74-82.
194. Labat C, Lacolley P, Lajemi M, de Gasparo M, Safar ME, Benetos A. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet Hypertension 2001; 38: 439-43.
195. Richard V, Joannides R, Henry JP, Mulder P, Mace B, Guez D, et al. Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: Haemodynamic, biological and structural effects. J Hypertens 1996; 14: 1447-54.
196. Topouchian J, Brisac A-M, Pannier B, Vicaut E, Safar M. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: A double-blind comparative and crossover study. J Hum Hypertens 1998; 12: 181-7.
197. De Luca N, Rosiello G, Lamenza F. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolopril. Am J Cardiol 1992; 70: 52D-59D.
198. Schartl M, Bocksch WG, Dreysse S, Beckmann S, Franke O, Hunten U. Remodeling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens Suppl 1994; 12: S37-S42.
199. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral artery disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45: 1194-1199.
200. Asmar RG, London GM, O'Rourke ME, Safar ME; REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: A comparison with atenolol. Hypertension 2001; 38: 922-6.
201. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22: 1623-30.
202. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-62.
203. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
204. Klingbeil AU, John S, Schneider MP, Jacobi J,Weidinger G, Schmieder RE.AT-1 receptor blockade improves mentation index: A double-blind, randomised, controlled study. J Hypertens 2002; 20: 2423-8.
205. Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: Beyond blood pressure reduction.Am J Hypertens 2002; 15: 1092-5.
206. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens 2002; 15: 1087-1091.
207. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens 2000; 14: 541-6.
208. Shargorodsky M, Hass E, Boaz M, Gavish D, Zimlichman R. High dose treatment with angiotensin II receptor blocker in patients with hypertension: Differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 2008; 197: 303-10.
209. Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007; 20: 184-9.
210. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-5.
211. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-35.
212. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18: 50-5.
213. Davies J, Gavin A, Band M, Morris A, Struthers A. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. Br J Clin Pharmacol 2005; 59: 520-3.
214. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist. Circulation 1997; 96: 1593-7
215. d'Uscio LV, Barton M, Shaw S, Moreau P, Lüscher TF. Structure and function of small arteries in salt-induced hypertension. Effects of chronic endothelin-subtype-A-receptor blockade. Hypertension 1997; 30: 905-911.
216. Li JS, Schürch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 1996; 9: 803-11.
217. Intengan HD, Schiffrin EL. Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1. J Hypertens 1998; 16: 1907-1912.
218. Li JS, Turgeon A, Schiffrin EL. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Am J Hypertens 1998; 11: 554-62.
219. Karam H, Heudes D, Bruneval P, Gonzales MF, Löffler BM, Clozel M, Clozel JP. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 1996; 28: 379-85.
220. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': Beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23: 551-6
221. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
222. Pannier BM, Guerin AP, Chais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-adrenergic antagonist in essential hypertension. Clin Exp Pharmacol Physiol 2001; 28: 1074-7.
223. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: Differential effects on central blood pressure and aortic PWV. Am J Hypertens 2006; 19: 214-9.
224. Armentano RL, Graf S, Ramírez AJ, Espinosa JD, Brandani L, Baglivo H, et al. Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients. Medicina (B Aires) 2001; 61: 535-40.
225. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45: 1194-9.
226. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68: 61-4.
227. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989; 14: 14-21.
228. Mahmud A, Feely J. beta-adrenergic antagonists Reduce Aortic Stiffness in Hypertension but Nebivolol, Not Atenolol, Reduces Wave Reflection. Am J Hypertens 2008; 21: 663-7.
229. McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkinson IB, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44: 305-10.
230. Fukunaga H, Ohkubo T, Kobayashi M, Tamaki Y, Kikuya M, Obara T, et al. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. J Hypertens 2008; 26(4): 685-90.
231. Strbian D, Durukan A, Tatlisumak T. Rodent models of hemorrhagic stroke. Curr Pharm Des 2008; 14(4): 352-8.
232. Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des 2008; 14(24): 2385-400